Kristen Ambrose Vertex Pharmaceuticals Inc (VRTX) insider trading activity

Kristen Ambrose is SVP & Chief Accounting Officer of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 7,845 shares of VRTX, which is worth approximately $3.76 Million. The most recent transaction as insider was on Feb 26, 2025, when has been sold 1,241 shares (Common Stock) at a price of $479.61 per share, resulting in proceeds of $595,196. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 7.85K

4.6% 3M change

1.51% 12M change

Total Value Held $3.76 Million

Kristen Ambrose Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 26 2025	SELL Payment of exercise price or tax liability	$595,196 $479.61 p/Share	1,241 Reduced 13.66%	7,845 Common Stock
Feb 25 2025	SELL Open market or private sale	$425,159 $480.95 p/Share	884 Reduced 8.87%	9,086 Common Stock
Feb 24 2025	SELL Payment of exercise price or tax liability	$400,155 $483.28 p/Share	828 Reduced 7.67%	9,970 Common Stock
Feb 18 2025	SELL Open market or private sale	$305,345 $455.06 p/Share	671 Reduced 5.85%	10,798 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$261,391 $463.46 p/Share	564 Reduced 4.69%	11,469 Common Stock
Feb 12 2025	BUY Grant, award, or other acquisition	-	2,080 Added 14.74%	12,033 Common Stock
Feb 11 2025	SELL Open market or private sale	$632,726 $459.83 p/Share	1,376 Reduced 12.15%	9,953 Common Stock
Feb 10 2025	SELL Payment of exercise price or tax liability	$276,576 $467.98 p/Share	591 Reduced 4.96%	11,329 Common Stock
Feb 04 2025	BUY Grant, award, or other acquisition	-	4,420 Added 27.05%	11,920 Common Stock
Apr 02 2024	SELL Open market or private sale	$100,560 $419.0 p/Share	240 Reduced 3.1%	7,500 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$94,072 $418.1 p/Share	225 Reduced 2.82%	7,740 Common Stock
Feb 26 2024	SELL Open market or private sale	$375,893 $425.7 p/Share	883 Reduced 9.98%	7,965 Common Stock
Feb 23 2024	SELL Payment of exercise price or tax liability	$357,522 $431.79 p/Share	828 Reduced 8.56%	8,848 Common Stock
Feb 12 2024	SELL Open market or private sale	$577,409 $420.24 p/Share	1,374 Reduced 12.43%	9,676 Common Stock
Feb 09 2024	SELL Payment of exercise price or tax liability	$249,839 $422.74 p/Share	591 Reduced 5.08%	11,050 Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	1,853 Added 13.73%	11,641 Common Stock
Feb 06 2024	BUY Grant, award, or other acquisition	-	2,950 Added 23.16%	9,788 Common Stock
May 30 2023	SELL Open market or private sale	$95,317 $329.82 p/Share	289 Reduced 4.06%	6,838 Common Stock
Mar 31 2023	SELL Payment of exercise price or tax liability	$55,218 $313.74 p/Share	176 Reduced 2.41%	7,127 Common Stock
Feb 27 2023	SELL Open market or private sale	$348,243 $288.52 p/Share	1,207 Reduced 14.18%	7,303 Common Stock
Feb 24 2023	SELL Payment of exercise price or tax liability	$145,138 $289.12 p/Share	502 Reduced 5.57%	8,510 Common Stock
Feb 01 2023	BUY Grant, award, or other acquisition	-	5,516 Added 37.97%	9,012 Common Stock
Apr 25 2022	SELL Open market or private sale	$88,045 $269.25 p/Share	327 Reduced 8.55%	3,496 Common Stock
Apr 01 2022	SELL Payment of exercise price or tax liability	$36,043 $263.09 p/Share	137 Reduced 3.46%	3,823 Common Stock
Feb 01 2022	BUY Grant, award, or other acquisition	-	2,566 Added 39.32%	3,960 Common Stock

Kristen Ambrose

SVP & Chief Accounting Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX

Account